131 related articles for article (PubMed ID: 34958817)
1. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.
Tang LJ; Ma HL; Eslam M; Wong GL; Zhu PW; Chen SD; Leeming DJ; Karsdal M; Li G; Huang OY; Leung HH; Zhou YJ; Feng Q; Jiang P; Gao LM; Byrne CD; Targher G; George J; Wong VW; Zheng MH
Metabolism; 2022 Mar; 128():154958. PubMed ID: 34958817
[TBL] [Abstract][Full Text] [Related]
2. A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.
Eslam M; Wong GL; Hashem AM; Chan HL; Nielsen MJ; Leeming DJ; Chan AW; Chen Y; Duffin KL; Karsdal M; Schattenberg JM; George J; Wong VW
Am J Gastroenterol; 2021 May; 116(5):984-993. PubMed ID: 33252454
[TBL] [Abstract][Full Text] [Related]
3. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
Tang LJ; Sun DQ; Song SJ; Yip TC; Wong GL; Zhu PW; Chen SD; Karsdal M; Leeming DJ; Jiang P; Wang C; Chen Q; Byrne CD; Targher G; Eslam M; George J; Wong VW; Zheng MH
Liver Int; 2024 May; 44(5):1129-1141. PubMed ID: 38426611
[TBL] [Abstract][Full Text] [Related]
4. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD.
Tang LJ; Li G; Eslam M; Zhu PW; Chen SD; Leung HH; Huang OY; Wong GL; Zhou YJ; Karsdal M; Leeming DJ; Jiang P; Wang C; Yuan HY; Byrne CD; Targher G; George J; Wong VW; Zheng MH
Hepatol Int; 2023 Feb; 17(1):190-201. PubMed ID: 36152131
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
[TBL] [Abstract][Full Text] [Related]
6. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
[TBL] [Abstract][Full Text] [Related]
7. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.
Daniels SJ; Leeming DJ; Eslam M; Hashem AM; Nielsen MJ; Krag A; Karsdal MA; Grove JI; Neil Guha I; Kawaguchi T; Torimura T; McLeod D; Akiba J; Kaye P; de Boer B; Aithal GP; Adams LA; George J
Hepatology; 2019 Mar; 69(3):1075-1086. PubMed ID: 30014517
[TBL] [Abstract][Full Text] [Related]
8. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
[TBL] [Abstract][Full Text] [Related]
9. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease.
Chen X; Goh GB; Huang J; Wu Y; Wang M; Kumar R; Lin S; Zhu Y
J Clin Transl Hepatol; 2022 Aug; 10(4):589-594. PubMed ID: 36062270
[TBL] [Abstract][Full Text] [Related]
10. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
Armandi A; Rosso C; Younes R; Leeming DJ; Karsdal MA; Caviglia GP; Pérez-Diaz-Del-Campo N; D'Amato D; Abdulle A; Nicolosi A; Castelnuovo G; Saracco GM; Ribaldone DG; Bugianesi E
J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675579
[No Abstract] [Full Text] [Related]
11. Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosis.
Erhardtsen E; Rasmussen DGK; Frederiksen P; Leeming DJ; Shevell D; Gluud LL; Karsdal MA; Aithal GP; Schattenberg JM
JHEP Rep; 2021 Aug; 3(4):100317. PubMed ID: 34466796
[TBL] [Abstract][Full Text] [Related]
12. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.
Boyle M; Tiniakos D; Schattenberg JM; Ratziu V; Bugianessi E; Petta S; Oliveira CP; Govaere O; Younes R; McPherson S; Bedossa P; Nielsen MJ; Karsdal M; Leeming D; Kendrick S; Anstee QM
JHEP Rep; 2019 Sep; 1(3):188-198. PubMed ID: 32039369
[TBL] [Abstract][Full Text] [Related]
13. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
Cheung JTK; Zhang X; Wong GL; Yip TC; Lin H; Li G; Leung HH; Lai JC; Mahadeva S; Nik Mustapha NR; Wang XD; Liu WY; Wong VW; Chan WK; Zheng MH
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1194-1204. PubMed ID: 37724633
[TBL] [Abstract][Full Text] [Related]
14. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
[TBL] [Abstract][Full Text] [Related]
15. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
16. PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease.
Madsen BS; Thiele M; Detlefsen S; Kjaergaard M; Møller LS; Trebicka J; Nielsen MJ; Gudmann NS; Leeming DJ; Karsdal MA; Krag A;
Aliment Pharmacol Ther; 2021 Sep; 54(5):699-708. PubMed ID: 34251031
[TBL] [Abstract][Full Text] [Related]
17. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
[TBL] [Abstract][Full Text] [Related]
18. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
[TBL] [Abstract][Full Text] [Related]
19. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.
Lykiardopoulos B; Hagström H; Fredrikson M; Ignatova S; Stål P; Hultcrantz R; Ekstedt M; Kechagias S
PLoS One; 2016; 11(12):e0167776. PubMed ID: 27936091
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
